Molecular diagnostic labs are increasingly turning to CGP and bringing the power of precision oncology directly into the hospital. However, implementing CGP testing in-house presents several onboarding and verification barriers. In this case study, learn how a leading academic medical center adopted the FDA-cleared PGDx elio™ tissue complete solution with faster time to market while reducing implementation burdens, increasing operational efficiency and simplifying the path to reimbursement.